arrow
M

Michael M. Givertz

Harvard Medical School
H指数:69
被引数:2.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comparable Rates of Severe Primary Graft DysfunctionAfter Heart Transplantation in Recipients With Prior LVAD or Other Cardiac Surgery: The Burden of Surgical Reentry

心脏移植后,具有先前左心室辅助装置或其他心脏手术史的患者发生严重原发性移植物功能障碍的相似发生率:再次手术的负担

2026-10-020
PRE
Impact of personalized risk communication on patient understanding and decision-making in LVAD therapy

个性化风险沟通对左心室辅助装置疗法中患者理解和决策的影响

2026-09-010
PRE
From Rescue to Interception: The PREVENT 2-LATE (PReserve Eligibility Via Early, Necessary Transfer) Framework for Advanced Heart Failure

从救援到拦截:PREVENT 2-LATE(通过早期必要转移保留资格)框架用于治疗心力衰竭

2026-08-270
PRE
Donor-Derived Cell-Free DNA as a Prognostic Biomarker After Heart Transplantation

供者衍生细胞外DNA作为心脏移植后预后生物标志物

2026-06-050
OAAI
Rationale and Design of the HeartShare/AMP-HF Deep Phenotyping Study to Improve Understanding of Heart Failure With Preserved Ejection Fraction

HeartShare/AMP-HF深度表型研究方案及其改善对射血分数保留型心力衰竭理解的原理

2025-12-010
PRE
Withdrawal of aspirin in patients with left ventricular assist device treated with vitamin K antagonists: impact of anticoagulation quality in the randomized ARIES-HM3 trial

左心室辅助装置且接受维生素K拮抗剂治疗的患者停用阿司匹林:随机ARIES-HM3试验中抗凝质量的影响

2025-11-011
OA
Comparison of The Burden of Cardiovascular-Kidney-Metabolic Syndrome Components in Heart Failure with Preserved Ejection Fraction clinical trials and Heart Failure in the General United States Population

比较心血管-肾脏-代谢综合征组分在射血分数保留的心力衰竭临床试验与全美普通人群中心力衰竭中的负担

2024-11-120
PRE